Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Prognostic Value of Regnase-1 in High-Grade Soft Tissue Sarcoma: Favourable in UPS, Yet Inverted in Adjuvantly Irradiated Patients.Cancers · 2026
   Article
2. Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026
   Review
3. Exploiting signal transduction pathways for cancer therapy: insights from natural products in preclinical models.Frontiers in pharmacology · 2026
   Review
4. Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026
   Review
5. Enhancing prognostic precision: exploring the role of lung immune prognostic index in immunotherapy-treated soft tissue sarcoma patients-a retrospective study.Journal of orthopaedic surgery and research · 2025
   Article
6. Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development.Micromachines · 2025
   Review
7. Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.Heliyon · 2024
   Review
8. DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target.Chemical science · 2024
   Article
9. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology.NPJ precision oncology · 2024
   Review
10. Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors.Frontiers in medicine · 2024
    Review
11. Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France).The journal of liquid biopsy · 2023
    Review
12. Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?Biomarker research · 2023
    Review
13. A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation.Diagnostics (Basel, Switzerland) · 2023
    Article
14. Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression ofInternational journal of molecular and cellular medicine · 2023
    Article
15. Simplifying the complex: accessible microfluidic solutions for contemporary processes withinLab on a chip · 2022
    Review
16. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.Frontiers in medicine · 2022
    Article
17. Biomarkers for neurodegenerative diseases in regulatory decision-making by the European Medicines Agency.Alzheimer's & dementia (New York, N. Y.)
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as